Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Climb Bio ( (CLYM) ) just unveiled an announcement.
On April 27, 2026, Climb Bio, Inc. entered into a securities purchase agreement with a group of institutional accredited investors, including an affiliate of RA Capital Management, to raise approximately $110 million through a private placement of 9,481,000 common shares at $9.50 each and pre-funded warrants for 2,106,000 additional shares at $9.4999 each. The deal, announced publicly on April 28 and expected to close on or about April 29, 2026, is structured under Regulation D and includes detailed ownership caps on warrant exercises, resale registration rights for investors, and standard indemnification provisions, with the added capital expected to extend Climb Bio’s cash runway and support continued progress of its late-stage development programs in immune-mediated diseases.
The most recent analyst rating on (CLYM) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Climb Bio stock, see the CLYM Stock Forecast page.
Spark’s Take on CLYM Stock
According to Spark, TipRanks’ AI Analyst, CLYM is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, widening losses, and increasing cash burn that elevates funding risk). This is partially offset by strong technical strength (price well above key moving averages with positive MACD), though overbought readings temper the technical score. Valuation provides limited support due to negative earnings and no dividend yield data.
To see Spark’s full report on CLYM stock, click here.
More about Climb Bio
Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing high-impact, disease-modifying therapeutics for immune-mediated diseases, including kidney-related conditions. Its pipeline includes budoprutug, an anti-CD19 monoclonal antibody targeting a broad range of B-cell-mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody in development for IgA nephropathy.
Average Trading Volume: 567,257
Technical Sentiment Signal: Buy
Current Market Cap: $436.6M
See more data about CLYM stock on TipRanks’ Stock Analysis page.